Related Experiment Video

Updated: May 25, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction

Giacomo Levantesi1, Rosa Maria Marfisi, Maria Grazia Franzosi

  • 1Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy.

International Journal of Cardiology
|January 21, 2012
PubMed

Insights

High uric acid (UA) levels are linked to increased risk of death and cardiovascular events (CVE). This study suggests UA should be considered a significant cardiovascular risk factor.

Area of Science:

  • Cardiovascular Medicine
  • Clinical Research
  • Biomarkers

Background:

  • Uric acid (UA) is not traditionally recognized as a cardiovascular risk factor.
  • Emerging evidence suggests a potential association between UA levels and cardiovascular diseases (CVD).

Purpose of the Study:

  • To investigate the relationship between uric acid levels and the risk of total mortality and cardiovascular events (CVE).
  • To evaluate the incremental prognostic value of UA in predicting cardiovascular outcomes.

Main Methods:

  • Analysis of data from 10,840 patients in the GISSI-Prevenzione trial.
  • UA levels were categorized into quintiles for risk assessment.
  • Multivariable analysis, AUC, NRI, and IDI tests were employed to evaluate prognostic accuracy.

Main Results:

  • A statistically significant association was found between high UA levels (quintile 5) and increased risk of total mortality (HR 1.63, P<0.0001) and CVE (HR 1.38, P=0.002).
  • Adding UA to classical risk factors significantly improved the prognostic accuracy of prediction models for CVE (AUC P=0.0041, NRI P=0.0004, IDI P<0.0001).

Conclusions:

  • Elevated uric acid levels may be considered a significant risk factor for mortality and cardiovascular events.
  • UA has incremental prognostic value, suggesting its inclusion in cardiovascular risk assessment.
Abstract

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...